Literature DB >> 25395239

Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995-2009.

Tzer-Zen Hwang1, Jenn-Ren Hsiao2, Chia-Rung Tsai3, Jeffrey S Chang3.   

Abstract

Recent studies suggested that human papillomavirus (HPV) is an emerging risk factor of head and neck cancer (HNC), particularly for oropharyngeal cancer. Studies from the West showed a rising trend of HPV-related HNC despite a decrease of the overall HNC incidence. In contrast, the overall HNC incidence in Taiwan has continued to rise. It is not clear whether the incidence trends of HPV-related HNC in Taiwan have a similar pattern to those from countries with an overall decreasing incidence of HNC. This study examined the incidence trends of HPV-related and HPV-unrelated HNC in Taiwan using data from the Taiwan Cancer Registry. Our results showed that the incidence trends of HPV-related and HPV-unrelated HNC in Taiwan both rose during 1995-2009. The incidence of HPV-related HNC (1.3 per 100,000 in 1995 to 3.3 in 2009, annual percentage change (APC) = 6.9, p < 0.0001) rose more rapidly than the incidence of HPV-unrelated HNC (10.4 per 100,000 in 1995 to 21.7 in 2009, APC = 5.0, p < 0.0001). The rising trend of HPV-related HNC was particularly prominent for HNC occurring in tonsil (APC = 8.2, p < 0.0001), in men (APC = 7.5, p < 0.0001), and in those aged between 40 and 50 years (APC = 8.5, p < 0.0001). Although the overall incidence of HNC in Taiwan has continued to increase, the most rapid rise is in the HPV-related HNC. This suggests that similar to the Western world, HPV-related HNC is becoming an important public health issue in Taiwan.
© 2014 UICC.

Entities:  

Keywords:  Taiwan; head and neck cancer; human papillomavirus

Mesh:

Year:  2014        PMID: 25395239     DOI: 10.1002/ijc.29330

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

1.  Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy.

Authors:  Maria B Koenigs; Armida Lefranc-Torres; Juliana Bonilla-Velez; Krupal B Patel; D Neil Hayes; Krzysztof Glomski; Paul M Busse; Annie W Chan; John R Clark; Daniel G Deschler; Kevin S Emerick; Rebecca J Hammon; Lori J Wirth; Derrick T Lin; Edmund A Mroz; William C Faquin; James W Rocco
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

Review 2.  Human papillomavirus associated head and neck squamous cell carcinoma: Controversies and new concepts.

Authors:  Nuzhat Husain; Azfar Neyaz
Journal:  J Oral Biol Craniofac Res       Date:  2017-09-01

3.  Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting.

Authors:  V C Sandulache; Y L Lei; L E Heasley; M Chang; C I Amos; E M Sturgis; E Graboyes; E Y Chiao; N Rogus-Pulia; J Lewis; A Madabhushi; M J Frederick; A Sabichi; M Ittmann; W G Yarbrough; C H Chung; R Ferrarotto; Weiyuan Mai; H D Skinner; U Duvvuri; P Gerngross; A G Sikora
Journal:  Oral Oncol       Date:  2019-10-22       Impact factor: 5.337

Review 4.  Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma.

Authors:  Maura L Gillison; Anil K Chaturvedi; William F Anderson; Carole Fakhry
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

5.  Incidence and Risk of Second Primary Malignant Neoplasm After a First Head and Neck Squamous Cell Carcinoma.

Authors:  Eric Adjei Boakye; Paula Buchanan; Leslie Hinyard; Nosayaba Osazuwa-Peters; Mario Schootman; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-08-01       Impact factor: 6.223

6.  Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer.

Authors:  Aimée R Kreimer; Mattias Johansson; Elizabeth L Yanik; Hormuzd A Katki; David P Check; Krystle A Lang Kuhs; Martina Willhauck-Fleckenstein; Dana Holzinger; Allan Hildesheim; Ruth Pfeiffer; Craig Williams; Neal D Freedman; Wen-Yi Huang; Mark P Purdue; Angelika Michel; Michael Pawlita; Paul Brennan; Tim Waterboer
Journal:  J Natl Cancer Inst       Date:  2017-08-01       Impact factor: 13.506

7.  Impact of HPV status on metastatic patterns and survival in non-oropharyngeal head and neck cancer with distant metastasis.

Authors:  Ping Wang; Shuang Zang; Miao Zhang; Guang Li; Yan Wang; Qiao Qiao
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-02-06       Impact factor: 2.503

8.  Tumor Volume Reduction Rate to Induction Chemotherapy is a Prognostic Factor for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Retrospective Cohort Study.

Authors:  Ting-Chun Lin; Chi-Hsien Huang; Ming-Yu Lien; Fu-Ming Cheng; Kai-Chiun Li; Chih-Yuan Lin; Ying-Chun Lin; Ji-An Liang; Ti-Hao Wang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

9.  Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI.

Authors:  Aimée R Kreimer; Anil K Chaturvedi; Laia Alemany; Devasena Anantharaman; Freddie Bray; Mary Carrington; John Doorbar; Gypsyamber D'Souza; Carole Fakhry; Robert L Ferris; Maura Gillison; D Neil Hayes; Allan Hildesheim; Shao Hui Huang; Luiz P Kowalski; Krystle A Lang Kuhs; James Lewis; Douglas R Lowy; Hisham Mehanna; Andy Ness; Michael Pawlita; Maisa Pinheiro; John Schiller; Meredith S Shiels; Joseph Tota; Lisa Mirabello; Saman Warnakulasuriya; Tim Waterboer; William Westra; Stephen Chanock; Paul Brennan
Journal:  Oral Oncol       Date:  2020-06-02       Impact factor: 5.337

10.  Investigating the association between serum human papillomavirus type 16 E7 antibodies and risk of head and neck cancer.

Authors:  Cheng-Chih Huang; Yu-Chu Su; Chan-Chi Chang; Wei-Ting Lee; Chun-Yen Ou; Yuan-Hua Wu; Shang-Yin Wu; Yu-Hsuan Lai; Jehn-Shyun Huang; Ken-Chung Chen; Wei-Ting Hsueh; Sen-Tien Tsai; Chia-Jui Yen; Jang-Yang Chang; Mei-Ling Tsai; Chen-Lin Lin; Ya-Ling Weng; Han-Chien Yang; Yu-Shan Chen; Jenn-Ren Hsiao; Jeffrey S Chang
Journal:  Cancer Med       Date:  2021-05-04       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.